Nls pharmaceutics submits plan to regain listing compliance with nasdaq

ZÜrich, switzerland / accesswire / february 23, 2024 / nls pharmaceutics ltd. (nasdaq:nlsp)(nasdaq:nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that it has submitted the company's plan, on time, to regain compliance with nasdaq listing rule 5550(b)(1).
NLSP Ratings Summary
NLSP Quant Ranking